SHORT REPORTS

Benign intracranial hypertension and Cushing's disease

Benign intracranial hypertension is found typically in obese young women, often associated with parity, the contraceptive pill, and other changes in hormonal state.¹ More rarely the syndrome is seen as a complication of Addison's disease, during withdrawal of corticosteroids, and in treatment with drugs such as nalidixic acid, nitrofurantoin, tetracycline, and indomethacin. An association with metabolic disorders such as carbon dioxide retention, hyponatraemic states and lead poisoning is also well known. A case is presented where benign intracranial hypertension was confirmed in a man with an adrenocorticotrophin-secreting pituitary microadenoma.

Case report

A constitutionally obese 18-year-old man was referred for investigation of delayed puberty. He had had occasional severe generalised headaches but no other complaints. He was of short stature (height 149.5 cm), grossly obese (weight 110 kg.), had scant body hair, prepubertal external genitalia, and a high-pitched voice. He had livid abdominal striae and predominantly centripetal fat distribution but no evidence of proximal myopathy or hypertension. He had bilateral papilloedema, confirmed by fluorescein angiography, but normal visual fields and acuity. Skull x-ray examination was normal and computerised tomographic (CT) scan and metrizamide cisternography, utilising CT scanning, showed normal ventricular size and no structural abnormality. A series of lumbar punctures confirmed benign intracranial hypertension, producing normal fluid at pressures between 20 and 40 cm H₂O. Full blood count, urea and electrolytes, blood gases, and glucose tolerance tests were normal. Skeletal radiographs showed a retarded bone age of 15 years. Steroid measurements showed raised urinary free cortisol concentrations (2900-4500 μ mol/l (95.12-163.13 ng/100 ml), reference range 550 (20)), loss of diurnal variation of plasma cortisol, absent suppression of steroid secretion with low-dose dexamethasone, partial suppression during high-dose dexamethasone treatment, and an exaggerated 17-hydroxycorticosteroid response during a metyrapone test. Pituitary driven Cushing's disease was confirmed by inappropriately high concentrations of ACTH. Growth hormone (GH) deficiency was shown by undetectable GH concentrations during insulin-induced hypoglycaemia. He was hypogonadal with a low plasma testosterone concentration (2.5 nmol/l (7.2 ng/100 ml) reference range 9-24 (25.9-59.1)), and diminished luteinising hormone (LH) and follicle-stimulating hormone (FSH) response to luteinising hormone-releasing hormone (LHRH). Prolactin concentrations, thyroid function, and urinary concentrating ability were normal.

After completing the endocrine investigations adrenal blockade was achieved with metyrapone and aminoglutethimide. Within four weeks of starting the blockade the patient's hypogonadism resolved, testosterone rising to 18.6 nmol/l (53.2 ng/100 ml). During adrenal blockade, however, he developed disabling raised-pressure headaches, which were not relieved by serial lumbar punctures and diuretic therapy, and the papilloedema progressed. Repeat CT scans were unchanged. A ventriculoatrial shunt was inserted and the headache and papilloedema resolved. After a period of strict dietary restriction while on adrenal blockade, during which he lost 25 kg in weight, a two-stage bilateral adrenalectomy was carried out. Nine months later, on replacement doses of corticosteroids, GH release in response to hypoglycaemia was normal, linear growth had resumed, genital growth had occurred, and his voice had broken. The pituitary-gonadal axis and thyroid function remained normal. Plasma ACTH concentrations had risen to expectedly high concentrations (453-526 ng/l (20.56-23.88 fg/100 ml) reference range 20-80 (0.9-3.6)) without clinical evidence of Nelson's syndrome. We propose to give external pituitary irradiation when linear growth has ceased.

Comment

We know of no previous report of a relationship between benign intracranial hypertension and Cushing's disease. Probably in our patient longstanding and relatively mild intracranial hypertension, secondary to hypercortisolism, was exacerbated by acute alteration of corticosteroid metabolism during adrenal blockade. The association of benign intracranial hypertension and other disordered states of adrenal function (Addison's disease, steroid withdrawal, obesity)² is well recognised and it is thought that alteration of the CSF absorption gradient across the arachnoid villi may be the primary factor in resetting intracranial fluid compartments.³ We suggest that in our patient the high circulating levels of adrenal steroids and their abrupt

reduction disturbed cerebral volume control and thus produced the manifestations of raised intracranial pressure.

- ¹ Donaldson JO. Neurology of pregnancy. In: Walton JN, ed. *Major problems in neurology*, vol 7. Philadelphia: WB Saunders, 1978:171-5.
- ² Paterson R, De Pasquale N, Mann S. Pseudotumour cerebri. *Medicine* 1961;40:85-9.
- ³ Johnston I, Paterson A. Benign intracranial hypertension. *Brain* 1974;97:301-12.

(Accepted 28 March 1980)

Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE

P K NEWMAN, MB, MRCP, senior neurological registrar
M SNOW, MB, MRCP, consultant physician
P HUDGSON, MB, FRCP, consultant neurologist

Platelet, granulocyte, and HLA antibodies in renal dialysis patients transfused with frozen blood

Prior blood transfusion is believed to enhance renal graft survival in both live-related and cadaver graft recipients. Nevertheless, transfusion may induce the production of lymphocytotoxic antibodies, and there is controversy about the importance of these in graft survival. We have operated a policy of minimal blood transfusion in our regular dialysis programme and of using, when possible, frozen washed red cells (frozen blood). Our original aim in using frozen blood was to reduce the risk of transmitting hepatitis, but we also hoped that the lower leucocyte and platelet contamination of frozen blood would reduce HLA alloimmunisation. Owing to this policy we have been able to study a group of patients who have received frozen blood as the only antigenic stimulus. Previous studies^{1,2} have concentrated on the development of lymphocytotoxic (HLA) antibodies in such patients, whereas our study also examines the sera of these patients for platelet and granulocyte specific alloantibodies.

Patients, methods, and results

We studied 34 patients maintained on regular dialysis treatment (RDT) for between 1 and 106 months (mean 34 months). Fifteen patients had had no antigenic stimulus such as a blood transfusion, pregnancy, or failed renal graft, and they served as a negative control group. The remaining 19 patients were transfused with frozen blood as the only antigenic stimulus. They received an average of 5 units each (range 1-12 units). Blood was frozen by a low-glycerol liquid nitrogen technique and processed for transfusion as described by Jenkins and Blagdon.³ All serum samples were screened for platelet and leucocyte antibody. Tests included the standard lymphocyte cytotoxicity test (LCT) and the lymphocyte (LIFT), granulocyte (GIFT), and platelet (PIFT) immunofluorescence tests developed at the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service in Amsterdam.

The control group of 15 patients without antigenic stimulus had negative results on antibody screening: they were excluded from subsequent calculations. Nine (47%) of the 19 patients transfused with frozen blood had antibodies as determined by a positive result in one or more of the screening tests (LCT, LIFT, GIFT, PIFT). When considered in terms of the methods used the results were positive with the LCT or LIFT, or both (indicating HLA specificity) in only two (10%) of these 19 patients. A further seven patients (37%) were alloimmunised to platelet specific (PIFT positive) or to granulocyte specific (GIFT positive) antigens, or to both. In these patients the LCT and LIFT were both negative.

Comment

A recent study has shown that a red cell suspension prepared from frozen blood is effectively depleted of leucocyte and platelet contamination.⁴ Nevertheless, our study has shown that the residual material can immunise the recipient against leucocyte and platelet

antigens. The incidence of HLA alloimmunisation in our study is comparable with that reported by Polesky¹ and Perkins² for similar groups of patients receiving frozen blood as the only antigenic stimulus. By including appropriate immunofluorescence tests our study has shown that platelet and granulocyte specific antibodies are more common in these patients (37%) than HLA antibodies (10%). This pattern of immunisation may reflect differences in the residual amounts of antigenic material in the transfused frozen blood and the relative antigenicity of the different cells.

These findings and the doubt whether pretransplant transfusion of frozen blood protects against graft rejection to the same extent as does whole blood suggest that there is little advantage in using frozen blood in potential kidney transplant recipients. Platelet and granulocyte specific antibodies are unlikely to affect renal transplantation, but immunisation against these antigens may significantly affect the results of bone marrow transplantation.⁵ A transfusion policy for prospective bone marrow transplant recipients should take into account this potential immunogenic effect of frozen blood.

AHW received a grant from St Bartholomew's Hospital Joint Research Board.

¹ Polesky HF. Clinical problems with HLA sensitisation. In: *Frozen-thawed red blood cells*. New York: Alan R Liss, 1976:141-55.

² Perkins HA. HLA antigens and blood transfusion: effect on renal transplants. *Transplant Proc* 1977;9, Suppl 1:229-32.

³ Jenkins WJ, Blagdon J. The longterm storage of blood for transfusion using an improved container for freezing the red cells in liquid nitrogen. *J Clin Pathol* 1971;24:685-9.

⁴ Amer KA, Pepper DS, Urbaniak SJ. Lymphocyte, granulocyte and platelet contamination of blood frozen by the low-glycerol liquid nitrogen technique. *Br J Haematol* 1980;44:253-61.

⁵ Blaschke J, Sorensen RU, Thompson JS, Polmar SH. Clinical relevance of granulocytotoxic antibodies in human transplantation. *Transplant Proc* 1977;9:1899-1901.

(Accepted 18 April 1980)

St Bartholomew's Hospital and Medical College, London EC1A 7BE

R M MINCHINTON, FAIMLS, research assistant, blood transfusion laboratory

A H WATERS, PHD, FRCPATH, reader in haematology and consultant haematologist

L R I BAKER, MD, FRCP, consultant nephrologist

W R CATTELL, MD, FRCP, consultant nephrologist

Effect of age on pelvic inflammatory disease in nulliparous women using a copper 7 intrauterine contraceptive device

The introduction of copper intrauterine contraceptive devices (IUCDs) in the early 1970s was an innovation as their small size and consequent ease of insertion meant that they could be used by nulliparous women, a group for whom IUCDs had been contraindicated. Recently, however, the use of IUCDs by nulliparae has been questioned. This is partly because of the associated risk of pelvic inflammatory disease, which may lead to infertility.¹ We report on factors affecting the incidence of this disease in a sample of nulliparous women using the copper 7 IUCD.

Patients, methods, and results

Between July 1975 and June 1976, 871 nulliparous women aged 16-49 attending the Margaret Pyke family planning clinic had an IUCD (copper 7) inserted for the first time. None showed clinical evidence of pelvic inflammatory disease at the time of insertion. A check up was advised at three months and then every six months. Women who missed an appointment were written to immediately. If they did not respond a duplicate letter was sent during the next month. At each visit side effects and information about pregnancy, expulsion, and removal were noted and the patient examined by the attending doctor for clinical evidence of pelvic inflammatory disease. Symptoms ranged from mild dyspareunia and pelvic tenderness to those severe enough to warrant hospital admission. Life-table analyses were used to calculate net rates for the disease for the first segment of IUCD use.

The disease was diagnosed in 54 women during the 30 months after insertion. The incidence was highest during the first six months (3.4/100 women) then fell progressively in each successive six-month period (2.0, 1.3, 0.7, and 0.4 per 100 women respectively) (χ^2 for trend=7.8; $p<0.01$). The risk of developing the disease was strongly related to age (table). At every time interval the cumulative rates were appreciably higher in the younger women and decreased as age increased (χ^2 for trend=7.3; $p<0.01$). Other factors that might predispose to the disease were investigated. Of women with pelvic inflammatory disease, 3 (6%) reported a history of the disease, 14 (25%) a history of abortion, and 6 (11%) a difficult insertion. These results, however, were not significantly different from those in women without the disease (3%, 20%, and 9% respectively).

Cumulative rates for pelvic inflammatory disease per 100 women by age and duration of IUCD use. Numbers of cases given in parentheses

Duration of IUCD use (months)	Age group (years)				All ages (n=871)
	16-19 (n=61)	20-24 (n=413)	25-29 (n=312)	30-49 (n=85)	
6	5.3 (3)	3.7 (13)	3.2 (9)	1.2 (1)	3.4 (26)
12	9.4 (5)	6.3 (21)	4.8 (13)	1.2 (1)	5.4 (40)
18	9.4 (5)	8.6 (26)	6.1 (16)	1.2 (1)	6.6 (48)
24	14.2 (7)	9.0 (27)	6.5 (17)	1.2 (1)	7.3 (52)
30	14.2 (7)	9.4 (28)	7.0 (18)	1.2 (1)	7.7 (54)

Comment

Many studies have shown that the risk of pelvic inflammatory disease is greater in IUCD users than in non-users.^{2,3} Women with the disease are less likely to be using oral contraceptives^{2,3} or mechanical methods² than IUCDs. Our findings show that in a large sample of nulliparous women attending one centre, all of whom were using the same type of IUCD, the risk of the disease was further related to duration of use and to age. Our finding that the risk decreased progressively with duration of use is consistent with earlier reports.

The effect of age was striking. After two years 16 to 19-year-olds had an infection rate more than 10 times that of 30 to 49-year-olds. Gray,⁴ working from the data of Weström *et al*,² also showed that age may be an important determinant of IUCD-related pelvic inflammatory disease, younger women being at higher risk than older women. It is not surprising that this effect is found, since a similar pattern exists in the general population. Hospital data show that the peak rate of the disease occurs in the 15-24 age group, and that this decreases progressively as age increases.⁵ This may be because younger rather than older women are more likely to be exposed to sexually transmitted infections. Since the rates of pelvic inflammatory disease are initially higher in young women, and IUCD use increases the overall risk of the disease, the greatest effect of the IUCD-associated disease is in this age group.

Since pelvic inflammatory disease may lead to infertility, we advise careful counselling before use of the IUCD by nulliparous women, especially the very young.

We thank Ms Ann McCulloch and Ms Walli Bounds for help in collecting the data and Ms Eve Roman for help in computing.

Requests for reprints should be addressed to Margaret Booth.

¹ Guillebaud J. Pelvic inflammatory disease and IUCDs. *British Journal of Family Planning* 1978;4:25-30.

² Weström L, Bengtsson LP, Mardh PA. The risk of pelvic inflammatory disease in women using intrauterine contraceptive devices as compared to non-users. *Lancet* 1976;ii:221-4.

³ Eschenbach DA, Harnisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. *Am J Obstet Gynecol* 1977;128:838-50.

⁴ Gray RH. Pelvic inflammatory disease and intrauterine contraceptive devices. *Lancet* 1976;ii:521.

⁵ Beral V. An epidemiological study of recent trends in ectopic pregnancy. *Br J Obstet Gynaecol* 1975;82:775-82.

(Accepted 11 April 1980)

Department of Medical Statistics and Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT

MARGARET BOOTH, MSc, research fellow

VALERIE BERAL, MRCP, senior lecturer in epidemiology

Margaret Pyke Centre for Study and Training in Family Planning, London W1A 4HQ

JOHN GUILLEBAUD, FRCSed, MRCOG, medical director